Abvc Biopharma (ABVC) Current Taxes (2023 - 2026)

Abvc Biopharma's (ABVC) quarterly Current Taxes came in at $5888.0 in Q1 2026, down 50.79% quarter-over-quarter from $11964.0 in Q4 2025.

Analysis

Abvc Biopharma (ABVC) Current Taxes (2023 - 2026) Analysis & Trends

Abvc Biopharma (ABVC) has reported Current Taxes for 4 consecutive years, with $5888.0 the latest figure, recorded in Q1 2026.

For the quarter ending Q1 2026, Current Taxes changed N/A year-over-year to $5888.0; the trailing twelve-month figure through Mar 2026 stood at $5888.0 (changed N/A YoY), and the FY2025 full-year result was $11964.0, changed N/A from the prior year.
Current Taxes retreated to $5888.0 in Q1 2026 per ABVC's latest filing, from $11964.0 in the prior quarter.
Across five years, Current Taxes topped out at $112946.0 in Q4 2023 and bottomed at $5888.0 in Q1 2026.
Historically, Current Taxes has averaged $44766.5 across 4 years, with a median of $17742.5 in 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Taxes (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	-
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	-
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	-
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	49.00 Mn
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	-
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	-
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	86.90 Mn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	74.18 Mn
10	Abvc Biopharma	25.56 Mn	25.56 Mn	-	-

Historic Data

Download Data